Nasdaq-listed biotech company Windtree Therapeutics (WINT) announced that it has signed a common stock purchase agreement of up to $500 million to establish an equity credit line (ELOC), in addition to an additional stock purchase agreement valued at $20 million with Build and Build Corp.
The total financing size is up to $520 million, of which 99% will be used to purchase BNB. The company plans to officially start using funds after obtaining shareholder approval to increase the number of common shares authorized.
Windtree Therapeutics signs new $520 million financing agreement to purchase BNB
2025-07-25 02:38:35
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
BTC falls below $117,000Next article：
某巨鲸/机构近3个月已囤积并质押36.5万枚SOL，浮盈730万美元
